The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2028
Synopsis
The Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Agonist segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs include Roche, Regeneron Pharmaceuticals, Bayer, Santen Oy, and Kanghong Pharmaceuticals, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Agonist
Allosteric Modulator
Kinase Inhibitor
Monoclonal Antibody
Others
Market segment by Application, can be divided into
Hospital
Clinic
Others
Market segment by players, this report covers
Roche
Regeneron Pharmaceuticals
Bayer
Santen Oy
Kanghong Pharmaceuticals
Novartis
Eli Lilly and Company
TRACON Pharmaceuticals
Pfizer
GSK
BIOCAD
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs, with revenue, gross margin and global market share of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs from 2019 to 2022.
Chapter 3, the Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs research findings and conclusion, appendix and data source.
Geographical Area
Global
The Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Agonist segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs include Roche, Regeneron Pharmaceuticals, Bayer, Santen Oy, and Kanghong Pharmaceuticals, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Agonist
Allosteric Modulator
Kinase Inhibitor
Monoclonal Antibody
Others
Market segment by Application, can be divided into
Hospital
Clinic
Others
Market segment by players, this report covers
Roche
Regeneron Pharmaceuticals
Bayer
Santen Oy
Kanghong Pharmaceuticals
Novartis
Eli Lilly and Company
TRACON Pharmaceuticals
Pfizer
GSK
BIOCAD
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs, with revenue, gross margin and global market share of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs from 2019 to 2022.
Chapter 3, the Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs research findings and conclusion, appendix and data source.
Geographical Area
Global
Index1 Market Overview
1.1 Product Overview and Scope of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs
1.2 Classification of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs by Type
1.2.1 Overview: Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Type in 2021
1.2.3 Agonist
1.2.4 Allosteric Modulator
1.2.5 Kinase Inhibitor
1.2.6 Monoclonal Antibody
1.2.7 Others
1.3 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market by Application
1.3.1 Overview: Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size & Forecast
1.5 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Forecast by Region
1.5.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Region, (2017-2022)
1.5.3 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Prospect (2017-2028)
1.5.4 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Prospect (2017-2028)
1.5.6 South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Drivers
1.6.2 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Restraints
1.6.3 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Trends Analysis
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
2.1.4 Roche Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Roche Recent Developments and Future Plans
2.2 Regeneron Pharmaceuticals
2.2.1 Regeneron Pharmaceuticals Details
2.2.2 Regeneron Pharmaceuticals Major Business
2.2.3 Regeneron Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
2.2.4 Regeneron Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Regeneron Pharmaceuticals Recent Developments and Future Plans
2.3 Bayer
2.3.1 Bayer Details
2.3.2 Bayer Major Business
2.3.3 Bayer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
2.3.4 Bayer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Bayer Recent Developments and Future Plans
2.4 Santen Oy
2.4.1 Santen Oy Details
2.4.2 Santen Oy Major Business
2.4.3 Santen Oy Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
2.4.4 Santen Oy Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Santen Oy Recent Developments and Future Plans
2.5 Kanghong Pharmaceuticals
2.5.1 Kanghong Pharmaceuticals Details
2.5.2 Kanghong Pharmaceuticals Major Business
2.5.3 Kanghong Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
2.5.4 Kanghong Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Kanghong Pharmaceuticals Recent Developments and Future Plans
2.6 Novartis
2.6.1 Novartis Details
2.6.2 Novartis Major Business
2.6.3 Novartis Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
2.6.4 Novartis Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Novartis Recent Developments and Future Plans
2.7 Eli Lilly and Company
2.7.1 Eli Lilly and Company Details
2.7.2 Eli Lilly and Company Major Business
2.7.3 Eli Lilly and Company Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
2.7.4 Eli Lilly and Company Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Eli Lilly and Company Recent Developments and Future Plans
2.8 TRACON Pharmaceuticals
2.8.1 TRACON Pharmaceuticals Details
2.8.2 TRACON Pharmaceuticals Major Business
2.8.3 TRACON Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
2.8.4 TRACON Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 TRACON Pharmaceuticals Recent Developments and Future Plans
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business
2.9.3 Pfizer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
2.9.4 Pfizer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Pfizer Recent Developments and Future Plans
2.10 GSK
2.10.1 GSK Details
2.10.2 GSK Major Business
2.10.3 GSK Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
2.10.4 GSK Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 GSK Recent Developments and Future Plans
2.11 BIOCAD
2.11.1 BIOCAD Details
2.11.2 BIOCAD Major Business
2.11.3 BIOCAD Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
2.11.4 BIOCAD Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 BIOCAD Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Players Market Share in 2021
3.2.2 Top 10 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Players Head Office, Products and Services Provided
3.4 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Mergers & Acquisitions
3.5 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Market Share by Type (2017-2022)
4.2 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Application (2017-2022)
5.2 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Type (2017-2028)
6.2 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Application (2017-2028)
6.3 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country
6.3.1 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Country (2017-2028)
6.3.2 United States Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Forecast (2017-2028)
6.3.3 Canada Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Forecast (2017-2028)
6.3.4 Mexico Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Type (2017-2028)
7.2 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Application (2017-2028)
7.3 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country
7.3.1 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Country (2017-2028)
7.3.2 Germany Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Forecast (2017-2028)
7.3.3 France Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Forecast (2017-2028)
7.3.5 Russia Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Forecast (2017-2028)
7.3.6 Italy Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Type (2017-2028)
8.2 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Application (2017-2028)
8.3 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Region
8.3.1 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Region (2017-2028)
8.3.2 China Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Forecast (2017-2028)
8.3.3 Japan Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Forecast (2017-2028)
8.3.4 South Korea Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Forecast (2017-2028)
8.3.5 India Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Forecast (2017-2028)
8.3.7 Australia Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Type (2017-2028)
9.2 South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Application (2017-2028)
9.3 South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country
9.3.1 South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Country (2017-2028)
9.3.2 Brazil Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Forecast (2017-2028)
9.3.3 Argentina Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Type (2017-2028)
10.2 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Application (2017-2028)
10.3 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Country
10.3.1 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Country (2017-2028)
10.3.2 Turkey Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Forecast (2017-2028)
10.3.4 UAE Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of TablesList of Tables
Table 1. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million) by Region (2017-2022)
Table 5. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Region (2023-2028)
Table 6. Roche Corporate Information, Head Office, and Major Competitors
Table 7. Roche Major Business
Table 8. Roche Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
Table 9. Roche Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Regeneron Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 11. Regeneron Pharmaceuticals Major Business
Table 12. Regeneron Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
Table 13. Regeneron Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Bayer Corporate Information, Head Office, and Major Competitors
Table 15. Bayer Major Business
Table 16. Bayer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
Table 17. Bayer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Santen Oy Corporate Information, Head Office, and Major Competitors
Table 19. Santen Oy Major Business
Table 20. Santen Oy Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
Table 21. Santen Oy Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Kanghong Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 23. Kanghong Pharmaceuticals Major Business
Table 24. Kanghong Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
Table 25. Kanghong Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Novartis Corporate Information, Head Office, and Major Competitors
Table 27. Novartis Major Business
Table 28. Novartis Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
Table 29. Novartis Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Eli Lilly and Company Corporate Information, Head Office, and Major Competitors
Table 31. Eli Lilly and Company Major Business
Table 32. Eli Lilly and Company Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
Table 33. Eli Lilly and Company Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. TRACON Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 35. TRACON Pharmaceuticals Major Business
Table 36. TRACON Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
Table 37. TRACON Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Pfizer Corporate Information, Head Office, and Major Competitors
Table 39. Pfizer Major Business
Table 40. Pfizer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
Table 41. Pfizer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. GSK Corporate Information, Head Office, and Major Competitors
Table 43. GSK Major Business
Table 44. GSK Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
Table 45. GSK Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. BIOCAD Corporate Information, Head Office, and Major Competitors
Table 47. BIOCAD Major Business
Table 48. BIOCAD Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
Table 49. BIOCAD Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 51. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 52. Breakdown of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 53. Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Players Head Office, Products and Services Provided
Table 54. Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Mergers & Acquisitions in the Past Five Years
Table 55. Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs New Entrants and Expansion Plans
Table 56. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million) by Type (2017-2022)
Table 57. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Share by Type (2017-2022)
Table 58. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Forecast by Type (2023-2028)
Table 59. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Application (2017-2022)
Table 60. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Forecast by Application (2023-2028)
Table 61. North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Type (2017-2022) & (USD Million)
Table 62. North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Type (2023-2028) & (USD Million)
Table 63. North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Application (2017-2022) & (USD Million)
Table 64. North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Application (2023-2028) & (USD Million)
Table 65. North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Country (2017-2022) & (USD Million)
Table 66. North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Country (2023-2028) & (USD Million)
Table 67. Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Type (2017-2022) & (USD Million)
Table 68. Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Type (2023-2028) & (USD Million)
Table 69. Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Application (2017-2022) & (USD Million)
Table 70. Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Application (2023-2028) & (USD Million)
Table 71. Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Country (2017-2022) & (USD Million)
Table 72. Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Country (2023-2028) & (USD Million)
Table 73. Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Type (2017-2022) & (USD Million)
Table 74. Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Type (2023-2028) & (USD Million)
Table 75. Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Application (2017-2022) & (USD Million)
Table 76. Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Application (2023-2028) & (USD Million)
Table 77. Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Region (2017-2022) & (USD Million)
Table 78. Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Region (2023-2028) & (USD Million)
Table 79. South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Type (2017-2022) & (USD Million)
Table 80. South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Type (2023-2028) & (USD Million)
Table 81. South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Application (2017-2022) & (USD Million)
Table 82. South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Application (2023-2028) & (USD Million)
Table 83. South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Country (2017-2022) & (USD Million)
Table 84. South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Country (2023-2028) & (USD Million)
Table 85. Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Type (2017-2022) & (USD Million)
Table 86. Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Type (2023-2028) & (USD Million)
Table 87. Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Application (2017-2022) & (USD Million)
Table 88. Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Application (2023-2028) & (USD Million)
Table 89. Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Country (2017-2022) & (USD Million)
Table 90. Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Picture
Figure 2. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Type in 2021
Figure 3. Agonist
Figure 4. Allosteric Modulator
Figure 5. Kinase Inhibitor
Figure 6. Monoclonal Antibody
Figure 7. Others
Figure 8. Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Application in 2021
Figure 9. Hospital Picture
Figure 10. Clinic Picture
Figure 11. Others Picture
Figure 12. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 13. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Forecast (2017-2028) & (USD Million)
Figure 14. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Region (2017-2028)
Figure 15. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Region in 2021
Figure 16. North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Middle East and Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Drivers
Figure 22. Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Restraints
Figure 23. Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Trends
Figure 24. Roche Recent Developments and Future Plans
Figure 25. Regeneron Pharmaceuticals Recent Developments and Future Plans
Figure 26. Bayer Recent Developments and Future Plans
Figure 27. Santen Oy Recent Developments and Future Plans
Figure 28. Kanghong Pharmaceuticals Recent Developments and Future Plans
Figure 29. Novartis Recent Developments and Future Plans
Figure 30. Eli Lilly and Company Recent Developments and Future Plans
Figure 31. TRACON Pharmaceuticals Recent Developments and Future Plans
Figure 32. Pfizer Recent Developments and Future Plans
Figure 33. GSK Recent Developments and Future Plans
Figure 34. BIOCAD Recent Developments and Future Plans
Figure 35. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Share by Players in 2021
Figure 36. Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 37. Global Top 3 Players Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share in 2021
Figure 38. Global Top 10 Players Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share in 2021
Figure 39. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 40. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Share by Type in 2021
Figure 41. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share Forecast by Type (2023-2028)
Figure 42. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Share by Application in 2021
Figure 43. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share Forecast by Application (2023-2028)
Figure 44. North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Market Share by Type (2017-2028)
Figure 45. North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Market Share by Application (2017-2028)
Figure 46. North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Country (2017-2028)
Figure 47. United States Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Canada Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Mexico Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Market Share by Type (2017-2028)
Figure 51. Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Market Share by Application (2017-2028)
Figure 52. Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Country (2017-2028)
Figure 53. Germany Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. France Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. United Kingdom Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Russia Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Italy Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Market Share by Type (2017-2028)
Figure 59. Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Market Share by Application (2017-2028)
Figure 60. Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Region (2017-2028)
Figure 61. China Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Japan Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. South Korea Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. India Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Southeast Asia Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Australia Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Market Share by Type (2017-2028)
Figure 68. South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Market Share by Application (2017-2028)
Figure 69. South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Country (2017-2028)
Figure 70. Brazil Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Argentina Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Middle East and Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Market Share by Type (2017-2028)
Figure 73. Middle East and Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Sales Market Share by Application (2017-2028)
Figure 74. Middle East and Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Country (2017-2028)
Figure 75. Turkey Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Saudi Arabia Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. UAE Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Methodology
Figure 79. Research Process and Data Source
Published By : GlobalInfoResearch
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
